Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Ahead of Key Inflation Data
Dividend Roundup: Wells Fargo, General Motors, Merck, Delta Air Lines, and More
Bristol-Myers Gains After Q2 Beat and Late-stage Trial Win
AbbVie Analyst Ratings
Biogen-partnered Alzheimer's Therapy Fails to Clear EU Hurdle
Centene Posts Q2 Beat Despite Medicaid Headwinds
Walt Disney, Eli Lilly, AST SpaceMobile, DexCom, Tesla: Why These 5 Stocks Are On Investors' Radars Today
J&J Talc Bankruptcy Plan Appeal Denied
This DB Chart Shows How the Tech Selloff Is Driving Moves Throughout the Stock Market
Novo Nordisk Shares Decline Amid Competitive Pressure
Smart Money Is Betting Big In MRK Options
Is the weight loss drug industry about to change? Viking Therapeutics rose nearly 40% intraday and hit a two-month high.
After communicating with the regulatory institution FDA, USA's Viking Therapeutics is pushing forward the weight-loss candidate drug VK2735 to phase III clinical trials ahead of schedule, potentially bringing the launch time forward by one year. This drug is expected to be injected once a month, which is more convenient than the same miraculous drug from Eli Lilly and Co and Novo Nordisk A/S. The oral version of VK2735 will start mid-term trials in the fourth quarter of this year.
Behind the Scenes of Abbott Laboratories's Latest Options Trends
Viking Therapeutics Stock Surges 31% As Company Advances Weight Loss Drug To Late-Stage Trial
What's Going On With Pfizer Stock Thursday?
Stocks Rebound As US Economy Flexes Muscles, Small Caps Rally, Gold Falls: What's Driving Markets Thursday?
AC Immune Stock Climbs 7% on FDA Fast Track Status for Alzheimer's Drug
Why Eli Lilly and Company Shares Are Moving Lower On Thursday
Pfizer Hemophilia B Gene Therapy Durveqtix Wins EC Authorization
Market Whales and Their Recent Bets on AMGN Options